RHEONIX develops automated molecular testing solutions for interchangeable purification, amplification and detection.
Rheonix, Inc. operates as a biomedical device company. Its products include CARD (Chemistry And Reagent Device) system to miniaturize and automate new and existing assays in multiple fields. Its products and technology are used in human/veterinary in vitro diagnostics, food/water testing, SNP analysis for personalized medicine applications, homeland security/defense applications, process control and final product QC, and tissue culture analysis in a research or production setting. Rheonix, Inc. was founded in 2007 and is based in Ithaca, New York.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 13, 2019 | Convertable Note | — | 1 | — | — | Detail |
Oct 20, 2015 | Series Unknown | $28.60M | 2 | — | — | Detail |
Jun 18, 2015 | Debt Financing | — | 1 | — | — | Detail |
Jul 1, 2014 | Debt Financing | — | 1 | — | — | Detail |
Oct 25, 2013 | Series A | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Advantage Capital | — | Convertable Note |
Onondaga Venture Capital Fund | — | Series Unknown |